close

News

LATEST POSTS from News

Hide-and-seek can lead to higher drug prices

Hide-and-seek can lead to higher drug prices In Switzerland and other European countries, drug prices are regulated to ensure affordable access to drugs. In the last few years, many European countries have introduced rebate schemes for drugs. In most cases, however, the rebates negotiated with the manufacturer are confidential. This…..

Ultragenyx will build a new gene therapy manufacturing facility in Bedford (MA)

Ultragenyx will build a new gene therapy manufacturing facility in Bedford Ultragenyx Pharmaceutical, a US biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases, plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts.…..

Minaris Regenerative Medicine will produce Mustang Bio’s MB107 lentiviral gene therapy for the treatment of SCID

 Minaris Regenerative Medicine will produce Mustang Bio's MB107 lentiviral gene therapy for the treatment of SCID Mustang Bio, a US clinical-stage biopharmaceutical company focused on cell and gene therapies for the treatment of hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine, a leading global contract development…..

New CEO for Polyplus-transfection

New CEO for Polyplus-transfection Polyplus-transfection, a leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, named Mario Philips as Chief Executive Officer. He succeeds Karsten Wilking, who will transition into a strategic advisor role. Prior to this appointment, Mario Philips served as CEO of…..

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment   The European Investment Bank (EIB) and Atriva Therapeutics, a german biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement  to facilitate the company’s development and clinical testing of…..